US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Skye Bioscience Inc.

2.43

+0.280013.02%

Post-market: 2.40-0.0300-1.23%19:54 EDT

Volume:342.98K

Turnover:823.04K

Market Cap:75.29M

PE:-2.93

High:2.48

Open:2.17

Low:2.17

Close:2.15

Loading ...

Overview Company News Filings

Crude Oil Moves Lower; Citigroup Posts Upbeat Results

William Blair Sticks to Their Buy Rating for Skye Bioscience (SKYE)

BRIEF-Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model

BUZZ-Skye Bioscience rises after experimental weight-loss drug shows promise in mice

Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab and Tirzepatide Combination in Preclinical Model

THOMSON REUTERS

Skye Bioscience Inc - Nimacimab Phase 2a Top-Line Data Expected Late Q3/Early Q4 2025

THOMSON REUTERS

Skye Bioscience Inc - Nimacimab Shows Additive Weight Loss Effect With Tirzepatide in Dio Model

THOMSON REUTERS

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Skye Bioscience Is Maintained at Buy by Craig-Hallum

Skye Bioscience Price Target Maintained With a $15.00/Share by Citizens Capital Markets

Skye Bioscience price target lowered to $14 from $18 at Craig-Hallum

Skye Bioscience (SKYE) Receives a Buy from Cantor Fitzgerald

Skye Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary

BRIEF-Skye Bioscience Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Business Update

Skye Bioscience Q4 2024 GAAP EPS $(0.24) Beats $(0.27) Estimate

Skye Bioscience Inc: Cash Runway Projected Through at Least Q1 2027

THOMSON REUTERS

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

THOMSON REUTERS

Press Release: Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Calendar of U.S. Earnings Expected in the Week Ahead

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SKYE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SKYE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","market":"US","secType":"STK","nameCN":"Skye Bioscience Inc.","latestPrice":2.43,"timestamp":1749240000000,"preClose":2.15,"halted":0,"volume":342981,"hourTrading":{"tag":"盘后","latestPrice":2.4,"preClose":2.43,"latestTime":"19:54 EDT","volume":7882,"amount":19000.325,"timestamp":1749254070956},"delay":0,"floatShares":16089235,"shares":30984358,"eps":-0.829901,"marketStatus":"Market Closed","change":0.28,"latestTime":"06-06 16:00:00 EDT","open":2.17,"high":2.48,"low":2.17,"amount":823042.5881940001,"amplitude":0.144186,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.829901,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"symbolChange":{"newSymbol":"SKYED","executeDate":"2023-09-08"},"adr":0,"exchange":"NASDAQ","adjPreClose":2.15,"preHourTrading":{"tag":"盘前","latestPrice":2.25,"preClose":2.15,"latestTime":"09:18 EDT","volume":922,"amount":2036.0950120000002,"timestamp":1749215922366},"postHourTrading":{"tag":"盘后","latestPrice":2.4,"preClose":2.43,"latestTime":"19:54 EDT","volume":7882,"amount":19000.325,"timestamp":1749254070956},"volumeRatio":1.1866023444132845,"impliedVol":2.2729,"impliedVolPercentile":0.72},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","floatShares":16089235,"roa":"-28.04%","roe":"-47.27%","lyrEps":-0.728135,"volumeRatio":1.1866023444132845,"shares":30984358,"dividePrice":0,"high":2.48,"amplitude":0.144186,"preClose":2.15,"low":2.17,"week52Low":1.14,"pbRate":"1.27","week52High":11.2,"institutionHeld":0,"latestPrice":2.43,"eps":-0.829901,"divideRate":0,"volume":342981,"delay":0,"ttmEps":-0.829901,"open":2.17,"prevYearClose":2.83,"prevWeekClose":1.98,"prevMonthClose":1.98,"prevQuarterClose":1.59,"fiveDayClose":1.98,"twentyDayClose":1.79,"sixtyDayClose":2.78},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SKYE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527447547","title":"Crude Oil Moves Lower; Citigroup Posts Upbeat Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2527447547","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527447547?lang=en_us&edition=fundamental","pubTime":"2025-04-16 00:10","pubTimestamp":1744733440,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44819308/dow-gains-100-points-citigroup-posts-upbeat-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","IE00BSNM7G36.USD","BK4608","LU2360032135.SGD","SKYE","MNQmain","LU2462157665.USD","MURA","LU0130102774.USD","NQmain","LU1267930227.SGD","APLD","LU2417539215.USD","PSQ","LU0106831901.USD","BK4116","LU0052756011.USD","BK4588","BK4609","BK4534","NVIW.SI","TQQQ","TSYW.SI","BK4583","USAW.SI","LU1791807156.HKD","C","QID","LU1201861249.SGD","USJW.SI","BK4023","LU2125154935.USD","BK4566","QLD","GOVX","LU0128525689.USD","RZLV","LU0648001328.SGD","LU0098860793.USD","SPRB","LU0320765646.SGD","LU0072461881.USD","BK4585","LU1668664300.SGD","LU0170899867.USD","LU2456880835.USD","LU0162691827.USD","SQQQ","BK4504"],"gpt_icon":1},{"id":"2527999442","title":"William Blair Sticks to Their Buy Rating for Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527999442","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527999442?lang=en_us&edition=fundamental","pubTime":"2025-04-15 23:45","pubTimestamp":1744731911,"startTime":"0","endTime":"0","summary":"In a report released today, Andy Hsieh from William Blair maintained a Buy rating on Skye Bioscience (SKYE – Research Report). The company’s shares...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-sticks-to-their-buy-rating-for-skye-bioscience-skye?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-sticks-to-their-buy-rating-for-skye-bioscience-skye?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE"],"gpt_icon":0},{"id":"2527416458","title":"BRIEF-Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2527416458","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527416458?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:51","pubTimestamp":1744721470,"startTime":"0","endTime":"0","summary":"BRIEF-Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical ModelApril 15 (Reuters) - Eli Lilly and Co LLY.N:SKYE BIOSCIENCE DEMONSTRATES OVER 30%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA5SCWWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1974910355.USD","SG9999014898.SGD","LU2491049909.HKD","SG9999015986.USD","LU2552382132.HKD","LU0354030438.USD","LU0466842654.USD","LU1868836914.USD","IE00B1BXHZ80.USD","SG9999001176.USD","SG9999015978.USD","LU2324357040.USD","LU2468319806.SGD","LU2237443465.HKD","LU0385154629.USD","LU2106854487.HKD","SKYE","BK4599","LU0471298694.HKD","LU2602419157.SGD","BK4516","LU0354030511.USD","LU2471134523.USD","LU2361045086.USD","LU0106261372.USD","LU0820561818.USD","LU1232071149.USD","LU1064131342.USD","LU0708995401.HKD","LU1093756168.USD","LU1720051017.SGD","SG9999015952.SGD","LU1280957306.USD","SG9999018865.SGD","LU1623119135.USD","SGXZ57979304.SGD","SGXZ81514606.USD","IE00BJT1NW94.SGD","LU0061475181.USD","LU1093756325.SGD","LU2264538146.SGD","LU1804176565.USD","LU0823416689.USD","LU2211815571.USD","LU2491050071.SGD","BK4007","LU0094547139.USD","LU1989771016.USD","LU1069344957.HKD"],"gpt_icon":1},{"id":"2527139244","title":"BUZZ-Skye Bioscience rises after experimental weight-loss drug shows promise in mice","url":"https://stock-news.laohu8.com/highlight/detail?id=2527139244","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527139244?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:20","pubTimestamp":1744719634,"startTime":"0","endTime":"0","summary":"BUZZ-Skye Bioscience rises after experimental weight-loss drug shows promise in mice** Shares of drug developer Skye Bioscience SKYE.O rise 11.5% to $1.46 premarket** Co says its drug candidate, nimacimab, showed 23.5% weight loss in mice, comparable to Eli Lilly's LLY.N popular drug, tirzepatide, sold as Zepbound, and Novo Nordisk's NOVOb.CO experimental drug, monlunabant** SKYE also says nimacimab, when combined with tirzepatide, showed a greater than 30% weight loss** Initial data from SKYE's mid-stage study in obesity is expected in late Q3/early Q4 2025** Up to last close, stock had fallen 53.7% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL6N3QT0KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU0943347566.SGD","BK4599","LU1127390331.HKD","BK4516","LU2063271972.USD","LU0061475181.USD","IE00BJJMRZ35.SGD","LU2237443465.HKD","LU1712237335.SGD","LU1551013425.SGD","LU0417517546.SGD","BK4139","LU2265009873.SGD","LU1551013342.USD","LU1983299246.USD","LU0079474960.USD","LU0820561818.USD","LU2237443978.SGD","IE00BJT1NW94.SGD","BK4581","LU0456855351.SGD","LU2471134952.CNY","SG9999015978.USD","SGXZ51526630.SGD","SGXZ57979304.SGD","SKYE","BK4588","LU1623119135.USD","LU1069344957.HKD","SG9999015952.SGD","IE00BK4W5M84.HKD","LU1917777945.USD","LU1974910355.USD","LU0471298777.SGD","IE00BFTCPJ56.SGD","LU2237443382.USD","LU2471134523.USD","SG9999017495.SGD","SG9999018865.SGD","SG9999014914.USD","LU1868836914.USD","LU1366192091.USD","IE0002141913.USD","LU0203202063.USD","LU1814569148.SGD","BK4533","IE00BK4W5L77.USD","LU1280957306.USD"],"gpt_icon":1},{"id":"2527496764","title":"Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab and Tirzepatide Combination in Preclinical Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2527496764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527496764?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA5SCWWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2552382215.SGD","LU1548497426.USD","LU2361045086.USD","LU1868837136.USD","LU2237443622.USD","IE00B1BXHZ80.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","SG9999014898.SGD","LU0122379950.USD","LU0198837287.USD","LU0385154629.USD","LU1623119135.USD","LU0354030511.USD","IE00BK4W5M84.HKD","LU1814569148.SGD","LU0820561909.HKD","LU0289739699.SGD","IE00BJLML261.HKD","LU2750360997.AUD","LU0354030438.USD","SGXZ31699556.SGD","LU1267930730.SGD","LU2089984988.USD","LU0256863811.USD","SGXZ99366536.SGD","LU2237443978.SGD","LU0320765059.SGD","LU0456855351.SGD","SG9999014906.USD","BK4585","LU2112291526.USD","LU2461242641.AUD","IE00B2B36J28.USD","LU2237438978.USD","BK4139","LLY","SG9999015952.SGD","IE0002141913.USD","LU2324357040.USD","IE00B4R5TH58.HKD","LU0708995401.HKD","LU0823416689.USD","LU0471298777.SGD","SG9999015986.USD","LU0058720904.USD","LU0882574139.USD","LU1551013425.SGD","SG9999018865.SGD","SKYE"],"gpt_icon":0},{"id":"2527449966","title":"Skye Bioscience Inc - Nimacimab Phase 2a Top-Line Data Expected Late Q3/Early Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527449966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527449966?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA5SCWWV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999015952.SGD","IE00BJJMRZ35.SGD","LU1868836914.USD","SG9999014898.SGD","LU1061106388.HKD","BK4533","BK4588","LU1804176565.USD","LU1267930730.SGD","LU2361045086.USD","LU1868837300.USD","LU0823416689.USD","LU1814569148.SGD","LU2552382058.USD","LU0097036916.USD","LU2552382132.HKD","LLY","SG9999001176.SGD","LU2471134796.USD","LU0256863811.USD","LU1232071149.USD","LU2361044949.HKD","LU0456855351.SGD","LU1720051017.SGD","LU0238689110.USD","IE00BJLML261.HKD","SG9999018865.SGD","LU1093756325.SGD","IE0002141913.USD","LU2360106947.USD","LU2491050071.SGD","LU2750360997.AUD","LU1064131342.USD","LU1023059063.AUD","LU1069344957.HKD","SG9999014906.USD","BK4585","LU2264538146.SGD","SKYE","LU1548497426.USD","LU2237443382.USD","IE00B1BXHZ80.USD","LU0689472784.USD","LU2750360641.GBP","SGXZ57979304.SGD","LU0466842654.USD","LU0094547139.USD","LU1551013342.USD","IE0004445239.USD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2527249965","title":"Skye Bioscience Inc - Nimacimab Shows Additive Weight Loss Effect With Tirzepatide in Dio Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2527249965","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527249965?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA5SCWWV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2360106947.USD","IE00B1BXHZ80.USD","LU1064131342.USD","LU1804176565.USD","IE0002141913.USD","IE0004445239.USD","LU0256863811.USD","LU2264538146.SGD","SG9999014906.USD","LU0689472784.USD","LU0114720955.EUR","BK4585","IE00BJLML261.HKD","LU2361045086.USD","LU0094547139.USD","LU0466842654.USD","LU1868836914.USD","LU2491050071.SGD","BK4588","LU1548497426.USD","LU1267930730.SGD","SGXZ57979304.SGD","LU0823416689.USD","BK4533","LU0097036916.USD","SG9999015952.SGD","SG9999018865.SGD","LU1868837300.USD","SG9999014898.SGD","LU2471134796.USD","LU2552382132.HKD","LU1061106388.HKD","LU2237443382.USD","SG9999001176.SGD","LU1023059063.AUD","LU1093756325.SGD","LU1720051017.SGD","LU2750360641.GBP","LU1069344957.HKD","LLY","LU1551013342.USD","LU2552382058.USD","LU2361044949.HKD","SKYE","IE00BJJMRZ35.SGD","LU0456855351.SGD","LU1814569148.SGD","LU0238689110.USD","LU1232071149.USD","LU2750360997.AUD"],"gpt_icon":0},{"id":"2527994734","title":"Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2527994734","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527994734?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model. “Skye believes nimacimab shows potential both as a monotherapy and in combination with a GLP-1 targeted drug to address unmet needs in obesity with the potential to change weight loss standards of care. Initial data from Skye’s Phase 2a study in obesity is expected in late Q3/early Q4 2025.”Skye also shared new in vitro potency data demonstrating that nimacimab’s non-competitive allosteric binding to CB1 provides for a differentiated and potentially advantageous mechanism of inhibition versus small molecules like monlunabant, which must compete with CB1 agonists. In this study, potency of nimacimab and monlunabant were assessed against two concentrations of the CB1 agonist CP55940. The first condition evaluated potency of e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skye-bioscience-demonstrates-over-30-110000609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2527158949","title":"Skye Bioscience to Conduct Meetings at Piper Sandler Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2527158949","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527158949?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:00","pubTimestamp":1744628400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 14, 2025  -- Skye Bioscience, Inc.  , a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that its executive team will be available for 1x1 meetings at the Piper Sandler Spring Biopharma Symposium on April 17th in Boston, MA.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skye-bioscience-conduct-meetings-piper-110000635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2521237218","title":"Skye Bioscience Is Maintained at Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2521237218","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521237218?lang=en_us&edition=fundamental","pubTime":"2025-03-22 01:12","pubTimestamp":1742577120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SKYE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 13:12 ET (17:12 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE"],"gpt_icon":0},{"id":"2521226234","title":"Skye Bioscience Price Target Maintained With a $15.00/Share by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2521226234","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521226234?lang=en_us&edition=fundamental","pubTime":"2025-03-22 00:27","pubTimestamp":1742574420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SKYE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 12:27 ET (16:27 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE"],"gpt_icon":0},{"id":"2521286580","title":"Skye Bioscience price target lowered to $14 from $18 at Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2521286580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521286580?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:40","pubTimestamp":1742560808,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Albert Lowe lowered the firm’s price target on Skye Bioscience (SKYE) to $14 from $18 and keeps a Buy rating on the shares. Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/skye-bioscience-price-target-lowered-to-14-from-18-at-craig-hallum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/skye-bioscience-price-target-lowered-to-14-from-18-at-craig-hallum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2521288263","title":"Skye Bioscience (SKYE) Receives a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2521288263","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521288263?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:57","pubTimestamp":1742558266,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Skye Bioscience (SKYE – Research Report) yesterday and set a price target of $1...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/skye-bioscience-skye-receives-a-buy-from-cantor-fitzgerald?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/skye-bioscience-skye-receives-a-buy-from-cantor-fitzgerald?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2521494398","title":"Skye Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2521494398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521494398?lang=en_us&edition=fundamental","pubTime":"2025-03-21 05:01","pubTimestamp":1742504512,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc reports results for the quarter ended December 31 - Earnings SummarySkye Bioscience Inc SKYE.OQ reported a quarterly adjusted loss of 24 cents per share for the quarter ended Decem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL8N3Q32DT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE"],"gpt_icon":0},{"id":"2521911044","title":"BRIEF-Skye Bioscience Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521911044","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521911044?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:49","pubTimestamp":1742503762,"startTime":"0","endTime":"0","summary":"BRIEF-Skye Bioscience Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Business UpdateMarch 20 (Reuters) - Skye Bioscience Inc SKYE.O:SKYE BIOSCIENCE REPORTS FOURTH QUARTER AND","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUABV7Z7Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2521149647","title":"Skye Bioscience Q4 2024 GAAP EPS $(0.24) Beats $(0.27) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2521149647","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521149647?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:10","pubTimestamp":1742501401,"startTime":"0","endTime":"0","summary":"Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44425003/skye-bioscience-q4-2024-gaap-eps-0-24-beats-0-27-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Skye Bioscience Q4 2024 GAAP EPS $(0.24) Beats $(0.27) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE"],"gpt_icon":0},{"id":"2521499315","title":"Skye Bioscience Inc: Cash Runway Projected Through at Least Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2521499315","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521499315?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:01","pubTimestamp":1742500861,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUABV7Z7Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2521496311","title":"Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496311?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:01","pubTimestamp":1742500861,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUABV7Z7Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2521496551","title":"Press Release: Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496551","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496551?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:01","pubTimestamp":1742500860,"startTime":"0","endTime":"0","summary":"-- Enrollment completed in Phase 2a CBeyond trial of CB1 inhibitor,-- Faster-than-expected enrollment enables full top-line Phase 2a data in. late Q3/early Q4 2025, ahead of schedule; interim analysis removed. -- Phase 2a dosing extended to 52 weeks to enhance long-term safety,\"Skye's prime accomplishment in 2024 was the initiation and rapid advancement of its comprehensive Phase 2a clinical study of nimacimab, a novel and differentiated CB1 inhibitor,\" said Punit Dhillon, President & CEO of Skye. \"Maturation of the obesity therapeutics landscape, including expanding clinical evidence, M&A, and licensing, highlights the strategic importance of alternative mechanisms of action with attributes differentiated from incretins. We believe nimacimab's product profile is well-positioned to potentially fulfill critical unmet needs in this rapidly evolving therapeutic area.exceeded the initial target of 120, with data blinded through the. -- Data Safety Monitoring Board reviews completed: Two in","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4139","BK4604","BK4555","TM","SKYE","BK4099","BK4585","BK4588"],"gpt_icon":0},{"id":"2520439968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520439968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520439968?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:00","pubTimestamp":1742464800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Amprius Tech Inc                                4Q      (.11)  4:05 PM. ·Lands' End Inc.                                   4Q       .57   6:45 AM. ·Lennar Corp Class A                              1Q      1.70       AMC","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JKS","BBNX","ASO","FLUX","NKTX","MREO","FBRX","TELA","DERM","MBRX","LPTX","IFRX","DRI","COYA","NKE","SOWG","SBS","OUST","KLC","RUM","BCAB","WOR","SKYE","BLRX","RLMD","LEN","SLS","CURV","JEF","LVTX","CELC","BRAG","PL","CBUS","PAYX","ACRV","CDLR","TH","TITN","THRD","MLKN","MNSO","ALUR","MGNX","BRNS","CMC","GDEV","SPRY"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SKYE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"SKYE","fiscalQuarterEnding":"2025/03","expectedEps":-0.31,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2025-03-20","symbol":"SKYE","fiscalQuarterEnding":"2024/12","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2024-11-07","symbol":"SKYE","fiscalQuarterEnding":"2024/09","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-08-09","symbol":"SKYE","fiscalQuarterEnding":"2024/06","expectedEps":-0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":-0.2},{"market":"US","date":"2024-05-10","symbol":"SKYE","fiscalQuarterEnding":"2024/03","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"post","actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SKYE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SKYE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.7143,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7143,"analysts":7,"updateTime":1740715200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SKYE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SKYE","date":"2025-06-06","current":-2.040261,"percent":0.886029,"low":-12.94129,"twenty":-7.099247,"median":-4.06458,"eighty":-2.616276,"high":-1.399078,"avg":-4.74008,"sd":2.539269,"marketCap":66616369},"quantilePoints":[{"date":"2024-04-12","current":-9.459964,"twenty":-9.513638,"median":-9.459964,"eighty":-7.885539,"marketCap":356118289},{"date":"2024-04-19","current":-12.650558,"twenty":-12.435864,"median":-9.657512,"eighty":-9.495746,"marketCap":476227531},{"date":"2024-04-26","current":-9.579238,"twenty":-12.081022,"median":-9.691058,"eighty":-9.561347,"marketCap":360608354},{"date":"2024-05-03","current":-9.683603,"twenty":-11.635233,"median":-9.68733,"eighty":-9.561347,"marketCap":364537161},{"date":"2024-05-10","current":-8.997775,"twenty":-10.807766,"median":-9.638876,"eighty":-9.507673,"marketCap":338719287},{"date":"2024-05-17","current":-9.168,"twenty":-10.15772,"median":-9.601602,"eighty":-9.22813,"marketCap":343770610},{"date":"2024-05-24","current":-8.952556,"twenty":-9.700003,"median":-9.54942,"eighty":-8.9931,"marketCap":335692167},{"date":"2024-05-31","current":-8.720508,"twenty":-9.691058,"median":-9.489815,"eighty":-8.983995,"marketCap":326991116},{"date":"2024-06-07","current":-8.47349,"twenty":-9.691058,"median":-9.389145,"eighty":-8.952556,"marketCap":317728707},{"date":"2024-06-14","current":-8.069277,"twenty":-9.691058,"median":-9.18753,"eighty":-8.690567,"marketCap":302572037},{"date":"2024-06-21","current":-6.684476,"twenty":-9.685094,"median":-9.060284,"eighty":-8.473188,"marketCap":250646409},{"date":"2024-06-28","current":-5.434411,"twenty":-9.674658,"median":-9.022864,"eighty":-8.245631,"marketCap":203773004},{"date":"2024-07-05","current":-5.58412,"twenty":-9.638876,"median":-8.993879,"eighty":-7.844715,"marketCap":209386586},{"date":"2024-07-12","current":-4.873005,"twenty":-9.631421,"median":-8.980898,"eighty":-7.11863,"marketCap":182722074},{"date":"2024-07-15","current":-4.820607,"twenty":-9.62993,"median":-8.974213,"eighty":-6.892464,"marketCap":180757321},{"date":"2024-08-02","current":-4.102007,"twenty":-9.628439,"median":-8.967527,"eighty":-6.745055,"marketCap":153812130},{"date":"2024-08-09","current":-3.735222,"twenty":-9.606075,"median":-8.870216,"eighty":-5.58412,"marketCap":140058855},{"date":"2024-08-16","current":-3.615791,"twenty":-9.579238,"median":-8.690567,"eighty":-4.690361,"marketCap":152904981},{"date":"2024-08-23","current":-3.787972,"twenty":-9.567311,"median":-8.506414,"eighty":-4.17237,"marketCap":160186171},{"date":"2024-08-30","current":-4.584307,"twenty":-9.543456,"median":-8.189044,"eighty":-4.185844,"marketCap":193861673},{"date":"2024-09-06","current":-4.347559,"twenty":-9.525571,"median":-8.069277,"eighty":-4.204574,"marketCap":183850037},{"date":"2024-09-13","current":-4.304513,"twenty":-9.489808,"median":-7.545298,"eighty":-4.204574,"marketCap":182029740},{"date":"2024-09-20","current":-3.93863,"twenty":-9.483818,"median":-7.11863,"eighty":-4.170873,"marketCap":166557212},{"date":"2024-09-27","current":-2.840979,"twenty":-9.431636,"median":-6.35886,"eighty":-4.072065,"marketCap":120139628},{"date":"2024-10-04","current":-2.56836,"twenty":-9.296072,"median":-5.58412,"eighty":-3.802872,"marketCap":108611078},{"date":"2024-10-11","current":-2.683147,"twenty":-9.199248,"median":-5.224584,"eighty":-3.740033,"marketCap":113465204},{"date":"2024-10-18","current":-3.034682,"twenty":-9.153032,"median":-4.873005,"eighty":-3.308736,"marketCap":128330966},{"date":"2024-10-25","current":-3.501004,"twenty":-9.080009,"median":-4.593919,"eighty":-3.325954,"marketCap":148050855},{"date":"2024-10-31","current":-3.651662,"twenty":-9.02741,"median":-4.557114,"eighty":-3.343172,"marketCap":154421896},{"date":"2024-11-08","current":-7.770049,"twenty":-9.018318,"median":-4.55561,"eighty":-3.379043,"marketCap":165040297},{"date":"2024-11-15","current":-7.870031,"twenty":-8.997775,"median":-4.571462,"eighty":-3.501004,"marketCap":167163977},{"date":"2024-11-22","current":-5.956085,"twenty":-8.989983,"median":-4.820607,"eighty":-3.501004,"marketCap":126510669},{"date":"2024-11-29","current":-6.413147,"twenty":-8.983995,"median":-4.921494,"eighty":-3.53544,"marketCap":136218922},{"date":"2024-12-06","current":-5.070528,"twenty":-8.981218,"median":-5.25247,"eighty":-3.595703,"marketCap":107700929},{"date":"2024-12-13","current":-4.784865,"twenty":-8.970201,"median":-5.21336,"eighty":-3.614356,"marketCap":101633271},{"date":"2024-12-20","current":-4.084989,"twenty":-8.95555,"median":-5.042643,"eighty":-3.644488,"marketCap":86767509},{"date":"2024-12-27","current":-3.799325,"twenty":-8.952556,"median":-4.89725,"eighty":-3.64221,"marketCap":80699851},{"date":"2025-01-03","current":-4.070706,"twenty":-8.886684,"median":-4.82416,"eighty":-3.64221,"marketCap":86464126},{"date":"2025-01-10","current":-4.427785,"twenty":-8.774403,"median":-4.734873,"eighty":-3.64221,"marketCap":94048699},{"date":"2025-01-17","current":-3.856458,"twenty":-8.71452,"median":-4.60353,"eighty":-3.6441,"marketCap":81913383},{"date":"2025-01-24","current":-3.727909,"twenty":-8.690567,"median":-4.558618,"eighty":-3.651662,"marketCap":79182936},{"date":"2025-01-31","current":-5.356192,"twenty":-8.660625,"median":-4.557114,"eighty":-3.694707,"marketCap":113768587},{"date":"2025-02-07","current":-4.256387,"twenty":-8.539337,"median":-4.55561,"eighty":-3.699343,"marketCap":90408104},{"date":"2025-02-14","current":-4.370652,"twenty":-8.47349,"median":-4.466458,"eighty":-3.699343,"marketCap":92835167},{"date":"2025-02-21","current":-4.470635,"twenty":-8.472282,"median":-4.477777,"eighty":-3.722196,"marketCap":94958847},{"date":"2025-02-28","current":-3.827892,"twenty":-8.245631,"median":-4.442068,"eighty":-3.730044,"marketCap":81306617},{"date":"2025-03-07","current":-3.670777,"twenty":-8.162365,"median":-4.40636,"eighty":-3.699343,"marketCap":77969405},{"date":"2025-03-14","current":-3.463671,"twenty":-8.134468,"median":-4.354733,"eighty":-3.698416,"marketCap":73570353},{"date":"2025-03-21","current":-2.203547,"twenty":-8.081254,"median":-4.304513,"eighty":-3.649772,"marketCap":58541914},{"date":"2025-03-28","current":-2.471704,"twenty":-7.90988,"median":-4.297339,"eighty":-3.6255,"marketCap":65666062},{"date":"2025-04-04","current":-1.632257,"twenty":-7.858605,"median":-4.256387,"eighty":-3.582221,"marketCap":43364381},{"date":"2025-04-11","current":-1.562303,"twenty":-7.846922,"median":-4.225597,"eighty":-3.501004,"marketCap":41505907},{"date":"2025-04-17","current":-1.842119,"twenty":-7.799915,"median":-4.189726,"eighty":-3.364695,"marketCap":48939801},{"date":"2025-04-25","current":-2.086958,"twenty":-7.727199,"median":-4.165203,"eighty":-3.259602,"marketCap":55444458},{"date":"2025-05-02","current":-2.366773,"twenty":-7.630073,"median":-4.156405,"eighty":-3.056205,"marketCap":62878352},{"date":"2025-05-09","current":-1.698098,"twenty":-7.560926,"median":-4.127838,"eighty":-2.911286,"marketCap":55444458},{"date":"2025-05-16","current":-1.907406,"twenty":-7.545298,"median":-4.116978,"eighty":-2.799369,"marketCap":62278559},{"date":"2025-05-23","current":-1.964344,"twenty":-7.500386,"median":-4.077848,"eighty":-2.746856,"marketCap":64137621},{"date":"2025-05-30","current":-2.011792,"twenty":-7.329718,"median":-4.070706,"eighty":-2.683147,"marketCap":65686838},{"date":"2025-06-06","current":-2.040261,"twenty":-7.099247,"median":-4.06458,"eighty":-2.616276,"marketCap":66616369}],"updateTime":1749361778893}}}